{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:35:46Z","timestamp":1770143746753,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA229697"],"award-info":[{"award-number":["R01 CA229697"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA236948"],"award-info":[{"award-number":["R01 CA236948"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.steroids.2023.109329","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T11:44:37Z","timestamp":1698147877000},"page":"109329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Navigating a plethora of progesterone receptors: Comments on the safety\/risk of progesterone supplementation in women with a history of breast cancer or at high-risk for developing breast cancer"],"prefix":"10.1016","volume":"200","author":[{"given":"Caroline H.","family":"Diep","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.steroids.2023.109329_b0005","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1093\/emboj\/17.7.2008","article-title":"Activation of the Src\/p21ras\/Erk pathway by progesterone receptor via cross-talk with estrogen receptor","volume":"17","author":"Migliaccio","year":"1998","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.steroids.2023.109329_b0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1097-2765(01)00304-5","article-title":"Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases","volume":"8","author":"Boonyaratanakornkit","year":"2001","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.steroids.2023.109329_b0015","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1128\/MCB.23.6.1994-2008.2003","article-title":"Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src\/Erk pathway in mammalian cells","volume":"23","author":"Ballare","year":"2003","journal-title":"Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.steroids.2023.109329_b0020","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1210\/endrev\/bnab041","article-title":"Membrane-Initiated Estrogen, Androgen, and Progesterone Receptor Signaling in Health and Disease","volume":"43","author":"Mauvais-Jarvis","year":"2022","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.steroids.2023.109329_b0025","doi-asserted-by":"crossref","first-page":"T35","DOI":"10.1530\/JME-19-0274","article-title":"90 years of progesterone: Steroid receptors as MAPK signaling sensors in breast cancer: let the fates decide","volume":"65","author":"Dwyer","year":"2020","journal-title":"J. Mol. Endocrinol."},{"issue":"7560","key":"10.1016\/j.steroids.2023.109329_b0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ERalpha action in breast cancer","volume":"523","author":"Mohammed","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.steroids.2023.109329_b0035","doi-asserted-by":"crossref","first-page":"e1501924","DOI":"10.1126\/sciadv.1501924","article-title":"Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer","volume":"2","author":"Singhal","year":"2016","journal-title":"Sci. Adv."},{"issue":"19","key":"10.1016\/j.steroids.2023.109329_b0040","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"Ebctcg, 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","volume":"377","author":"Pan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.steroids.2023.109329_b0045","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.molcel.2014.05.015","article-title":"Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance","volume":"54","author":"Easwaran","year":"2014","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.steroids.2023.109329_b0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/emmm.201303411","article-title":"Sox2 promotes tamoxifen resistance in breast cancer cells","volume":"6","author":"Piva","year":"2014","journal-title":"EMBO Mol. Med."},{"issue":"7","key":"10.1016\/j.steroids.2023.109329_b0055","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/0008-5472.CAN-17-0985","article-title":"Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ERalpha(+) Mammary Carcinomas","volume":"78","author":"Shea","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2023.109329_b0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semcancer.2020.10.008","article-title":"The impact of oral contraceptive use on breast cancer risk: State of the art and future perspectives in the era of 4P medicine","volume":"72","author":"Bonfiglio","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"4","key":"10.1016\/j.steroids.2023.109329_b0065","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jama.2020.9482","article-title":"Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women's health initiative randomized clinical trials","volume":"324","author":"Chlebowski","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.steroids.2023.109329_b0070","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/GME.0b013e3182936ef4","article-title":"Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo","volume":"21","author":"Ochnik","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2023.109329_b0075","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-10-1","article-title":"Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference","volume":"9","author":"Stevenson","year":"2020","journal-title":"Drugs Context"},{"issue":"12","key":"10.1016\/j.steroids.2023.109329_b0080","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S1470-2045(13)70448-0","article-title":"The sex hormone system in carriers of BRCA1\/2 mutations: a case-control study","volume":"14","author":"Widschwendter","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.steroids.2023.109329_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gde.2021.05.006","article-title":"Communication between chromatin and homologous recombination","volume":"71","author":"Verma","year":"2021","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"1","key":"10.1016\/j.steroids.2023.109329_b0090","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/me.2004-0488","article-title":"The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells","volume":"20","author":"Ma","year":"2006","journal-title":"Mol. Endocrinol."},{"issue":"2 Pt 1","key":"10.1016\/j.steroids.2023.109329_b0095","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/AOG.0000000000000356","article-title":"Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland","volume":"124","author":"Soini","year":"2014","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.steroids.2023.109329_b0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13058-021-01499-4","article-title":"The impact of breast density notification on rescreening rates within a population-based mammographic screening program","volume":"24","author":"Pirikahu","year":"2022","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.steroids.2023.109329_b0105","doi-asserted-by":"crossref","unstructured":"M. Archer, P. Dasari, A. Evdokiou, W.V. Ingman, Biological Mechanisms and Therapeutic Opportunities in Mammographic Density and Breast Cancer Risk, Cancers (Basel) 13(21) (2021).","DOI":"10.3390\/cancers13215391"},{"issue":"1","key":"10.1016\/j.steroids.2023.109329_b0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12672-021-00438-1","article-title":"Does circulating progesterone mediate the associations of single nucleotide polymorphisms in progesterone receptor (PGR)-related genes with mammographic breast density in premenopausal women?","volume":"12","author":"Akinjiyan","year":"2021","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.steroids.2023.109329_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.781066","article-title":"Breast cancer risk with progestin subdermal implants: a challenge in patients counseling","volume":"12","author":"Mohammed","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.steroids.2023.109329_b0120","unstructured":"M. Kumle, E. Weiderpass, T. Braaten, I. Persson, H.O. Adami, E. Lund, Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study, Cancer Epidemiol. Biomark. Prev. 11(11) (2002) 1375-81."},{"issue":"1","key":"10.1016\/j.steroids.2023.109329_b0125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199407073310102","article-title":"Transient increase in the risk of breast cancer after giving birth","volume":"331","author":"Lambe","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.steroids.2023.109329_b0130","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/oxfordjournals.aje.a010266","article-title":"Age at any full-term pregnancy and breast cancer risk","volume":"151","author":"Chie","year":"2000","journal-title":"Am. J. Epidemiol."},{"issue":"4","key":"10.1016\/j.steroids.2023.109329_b0135","first-page":"299","article-title":"Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden)","volume":"13","author":"Liu","year":"2002","journal-title":"Cancer Causes Control"},{"issue":"13","key":"10.1016\/j.steroids.2023.109329_b0140","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.steroids.2023.109329_b0145","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jamaoncol.2015.0494","article-title":"Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials","volume":"1","author":"Chlebowski","year":"2015","journal-title":"JAMA Oncol."},{"issue":"23","key":"10.1016\/j.steroids.2023.109329_b0150","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary Hormonal Contraception and the Risk of Breast Cancer","volume":"377","author":"Morch","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2023.109329_b0155","article-title":"Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study","author":"Burchardt","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.steroids.2023.109329_b0160","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/JME-14-0252","article-title":"Progesterone action in breast, uterine, and ovarian cancers","volume":"54","author":"Diep","year":"2015","journal-title":"J. Mol. Endocrinol."},{"issue":"3","key":"10.1016\/j.steroids.2023.109329_b0165","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/bjc.2013.344","article-title":"Hormonal risk factors and invasive epithelial ovarian cancer risk by parity","volume":"109","author":"Bodelon","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.steroids.2023.109329_b0170","first-page":"708","article-title":"A quantitative assessment of oral contraceptive use and risk of ovarian cancer","volume":"80","author":"Hankinson","year":"1992","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.steroids.2023.109329_b0175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13048-021-00911-z","article-title":"Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses","volume":"14","author":"Tanha","year":"2021","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.steroids.2023.109329_b0180","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnad018","article-title":"Re-evaluating the role of progesterone in ovarian cancer: is progesterone always protective?","author":"Mauro","year":"2023","journal-title":"Endocr. Rev."}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X23001575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X23001575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:12:42Z","timestamp":1758535962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X23001575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":36,"alternative-id":["S0039128X23001575"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2023.109329","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating a plethora of progesterone receptors: Comments on the safety\/risk of progesterone supplementation in women with a history of breast cancer or at high-risk for developing breast cancer","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2023.109329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109329"}}